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Abstract
Most antineoplastic chemotherapies eliminate cancer cells through activation of the mitochondria-controlled intrinsic
apoptotic pathway. Therein, BAX, BAK, and/or BOK function as the essential pore-forming executioners of
mitochondrial outer membrane permeabilization (MOMP). The activation threshold of BAX and BAK also correlates
inversely with the required strength of an apoptotic stimulus to induce MOMP and thereby effectively determines a
cell’s readiness to undergo apoptosis. Consequently, the ‘gatekeepers’ BAX and BAK emerged as therapeutic targets,
but functional or genetic loss renders BAX/BAK-targeting strategies prone to fail. Here, we show that the small
molecule Raptinal overcomes this limitation by triggering cytochrome c release in a BAX/BAK/BOK-independent
manner. Raptinal exerts a dual cytotoxic effect on cancer cells by rapid activation of the intrinsic apoptotic pathway
and simultaneous shutdown of mitochondrial function. Together with its efﬁcacy to eliminate cancer cells in vivo,
Raptinal could be useful in difﬁcult-to-treat cancer entities harboring defects in the intrinsic apoptosis pathway.
Introduction
Most antineoplastic chemotherapies rely on activation of
the mitochondria-controlled intrinsic apoptotic pathway to
eliminate cancer cells1. The key effector proteins for
intrinsic apoptosis, BAX, BAK, and/or BOK, form (once
activated) pores in the outer mitochondrial membrane and
cause mitochondrial outer membrane permeabilization
(MOMP)2–4. Subsequent cytochrome c release allows
assembly of the ‘apoptosome’ complex5. This scaffold fos-
ters activation of caspase-9, the prototypic initiator caspase
of the intrinsic apoptotic pathway. Caspase-9 in turn acti-
vates the effector caspases 3 and 7, both executioners of
apoptosis6. Notably, MOMP not only initiates the cascade-
like activation of caspases. Concomitant loss of mitochon-
drial transmembrane potential also severely compromises
the function of mitochondria. MOMP is therefore con-
sidered the point of no return and irrevocably condemns a
cell to death. Not surprisingly, the ‘MOMP gatekeepers’
BAX/BAK and their interplay with the regulatory network
of BCL-2 family proteins emerged as therapeutic targets in
cancer therapy4,7. Direct pharmacological targeting of BAX/
BAK or liberation from inhibitory BCL-2 family proteins
ultimately aim to initiate intrinsic apoptosis8–11. For cyto-
chrome c release and successful MOMP initiation, however,
BAX/BAK-targeting strategies critically depend on func-
tional pore-forming proteins and their readiness to be
activated (also referred to as ‘mitochondrial priming’)12.
Here, we report that Raptinal, a recently developed inducer
of intrinsic apoptosis in vitro and in vivo13, overcomes this
drawback. Raptinal rapidly triggers cytochrome c release in
a BAX-, BAK-, and BOK-independent manner. Raptinal
exerts a dual cytotoxic effect on cancer cells by rapid acti-
vation of the intrinsic apoptotic pathway and simultaneous
shutdown of mitochondrial function. Difﬁcult-to-treat
cancer entities with defects in the intrinsic apoptosis path-
way may thus still respond to Raptinal treatment.
© The Author(s) 2019
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Martin Ehrenschwender (martin.ehrenschwender@ukr.de)
1Department of Oral and Maxillofacial Surgery, University Hospital Regensburg,
Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany
2Institute of Clinical Microbiology and Hygiene, University Hospital
Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany
Full list of author information is available at the end of the article.
Edited by T. Kaufmann
Ofﬁcial journal of the Cell Death Differentiation Association
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
1
2
3
4
5
6
7
8
9
0
()
:,;
12
34
56
78
90
()
:,;
Results
Raptinal rapidly triggers apoptosis in cancer cells
Exposure to Raptinal showed cytotoxic effects in various
cancer cell lines and triggered rapid processing of
caspase-9 (Fig. 1a, b). Together with the observed cleavage
of caspase-3 (a substrate of caspase-9) and p70S6K (a
substrate of caspase-3), this indicated Raptinal-induced
activation of the intrinsic apoptosis pathway14. Likewise,
Raptinal-treated HCT116 cells stained positive for
annexin-V and were rescued by the pan-caspase inhibitors
zVAD-fmk and QVD-OPh (Fig. 1c, d). Deﬁciency of
caspase-8, the initiator caspase of the extrinsic apoptotic
pathway, had no protective effect and still allowed
Raptinal-induced effector caspase activation (Fig. 1e, f).
Taken together, our results are in agreement with the
original description of Raptinal as a rapid inducer of
apoptotic cell death via the intrinsic pathway13.
BAX and BAK are dispensable for Raptinal-induced
apoptosis
Inhibition of antiapoptotic BCL-2 family proteins facil-
itates activation of the pore-forming proteins BAX and/or
BAK and thus primes for intrinsic apoptosis15. The BH3
mimetic ABT-737 (targeting BCL-2, BCL-XL, and BCL-W)
expectedly primed HCT116 cells for death induced by the
MCL-1 inhibitor S63845. Surprisingly, neither S63845 nor
ABT-199 (targeting BCL-2) nor ABT-737 acted synergisti-
cally with Raptinal in killing HCT116 cells (Fig. 2a).
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Fig. 1 Raptinal triggers intrinsic apoptosis in various cancer cells. a HCT116, PCI-1 and Jurkat J16 cells were challenged with the indicated
concentrations of Raptinal for 18 h. Data points and mean ± SEM from three independent experiments are shown. b HCT116 cells were challenged with
Raptinal (10 µM) for the indicated periods of time in the absence and presence of the pan-caspase inhibitor zVAD-fmk (100 µM). After washing and lysis,
western blot analyses were performed with antibodies speciﬁc for the indicated proteins. Detection of tubulin served as a loading control.
c HCT116 cells were treated as in b and subsequently analyzed by ﬂow cytometry for 7-AAD- and annexin-V positivity. For b and c, data shown are
representative of two experiments performed. d, e HCT116 cells and caspase-8-deﬁcient variants thereof were challenged with Raptinal (10 µM) for 60min
or 120min in the presence and absence of the pan-caspase inhibitors zVAD-fmk (100 µM) or QVD-OPh (100 µM). f HCT116 Caspase-8 KO cells were treated
with Raptinal (10 µM) for the indicated periods of time in the presence and absence of zVAD-fmk (100 µM). Caspase-3/-7 activity was assessed using the
ﬂuorogenic substrate (DEVD)2-R110. For d–f, individual data points of at least two independent experiments are shown. RFU, relative ﬂuorescence units
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Fig. 2 BAX and BAK are dispensable for Raptinal-induced caspase activation. a HCT116 cells were challenged for 18 h with the indicated
concentrations of Raptinal and S63845 in the presence and absence of the indicated concentrations of ABT-199 (targeting BCL-2), ABT-737 (targeting
BCL-2, BCL-XL and BCL-W), and S63845 (targeting MCL-1). b, c HCT116 cells and BAX- or BAX/BAK-deﬁcient variants thereof were challenged with the
indicated concentrations of ABT-737 and Raptinal for 18 h. d HCT116 cells and BAX- or BAX/BAK-deﬁcient variants thereof were challenged with
Raptinal (10 µM) for the indicated periods of time in the absence and presence of the pan-caspase inhibitor zVAD-fmk (100 µM). After washing and
lysis, western blot analyses were performed with antibodies speciﬁc for the indicated proteins. Detection of tubulin served as a loading control. The
asterisk (*) indicates a defect in the CCD sensor of the western blot imaging system. All samples were run on the same gel, no gels were sliced.
e HCT116, HCT116 BAX KO and BAX/BAK DKO cells were treated with Raptinal (10 µM) for the indicated periods of time in the presence and absence
of zVAD-fmk (100 µM). Caspase-3/-7 activity was assessed using the ﬂuorogenic substrate (DEVD)2-R110. f, g HCT116, HCT116 BAX KO and BAX/BAK
DKO cells were challenged with Raptinal (10 µM) for the indicated periods of time in the presence and absence of zVAD-fmk (100 µM). For a–c data
points and mean ± SEM from three independent experiments are shown; for d, data shown are representative of two experiments performed; for
e–g, individual data points of at least two independent experiments are shown. RFU, relative ﬂuorescence units
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The loss of BAX was sufﬁcient to abrogate cytotoxicity of
ABT-737 in HCT116 cells, whereas cytotoxicity of Raptinal
was not depending on BAX or BAK (Fig. 2b, c). Proteolytic
processing and activation of initiator and effector caspases
was intact in Raptinal-treated BAX- and/or BAX/BAK-
deﬁcient HCT116 cells (Fig. 2d, e). Moreover, Raptinal
rapidly caused ‘membrane blebbing’, a morphological hall-
mark of apoptotic cell death, irrespective of BAX/BAK
(Fig. 3). Inhibition of caspase activity using zVAD-fmk
expectedly abrogated Raptinal-induced apoptotic mor-
phology (Fig. 3), reduced cytotoxicity (Fig. 2f, g) together
with annexin-V/7-AAD-positivity in BAX/BAK-deﬁcient
and -proﬁcient cells (Fig. 4a). Collectively, these results
demonstrate that Raptinal triggers apoptotic cell death in
the absence of the pore-forming proteins BAX/BAK.
Caspase-9 propagates Raptinal-induced apoptosis after
BAX/BAK-independent cytochrome c release
The loss of BAX/BAK is known to severely impair
activation of the mitochondria-controlled apoptotic cas-
cade16,17. The efﬁcient Raptinal-induced caspase activation
in BAX/BAK-deﬁcient cells (Fig. 2d, e) could therefore
either question an exclusive dependency of Raptinal on
intrinsic apoptosis or point to an alternative, BAX/BAK-
independent mechanism to initiate this pathway. Indeed,
the latter seems the case as even in the absence of BAX/
BAK Raptinal treatment resulted in cytochrome c release
from the mitochondria (Fig. 4b, c). The loss of caspase-9
did expectedly not affect Raptinal-induced cytochrome c
release (Fig. 4d), but conferred almost full-blown protec-
tion to Jurkat cells challenged with Raptinal (Fig. 4e).
Importantly, we conﬁrmed Raptinal-induced apoptosis in
BAX/BAK-deﬁcient DLD1 and SW48 cells to exclude cell
line-speciﬁc effects (Fig. 5). In sum, our data support a
model of fast Raptinal-induced activation of intrinsic
apoptosis through a BAX/BAK-independent mechanism
of cytochrome c release and subsequent caspase-9-
dependent propagation of the death signal.
BOK is dispensable for Raptinal-induced MOMP
BOK is another protein capable to form pores in the
outer mitochondrial membrane and has been reported to
Fig. 3 BAX/BAK-deﬁcient cells display morphological signs of apoptosis upon Raptinal treatment. HCT116, HCT116 BAX KO, and BAX/BAK
DKO cells were treated with Raptinal (10 µM) for the indicated periods of time in the presence and absence of zVAD-fmk (100 µM). Morphological
changes were documented by bright ﬁeld microscopy. Scale bar: 50 µm. Data shown are representative of two experiments performed
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induce cytochrome c release in the absence of BAX/
BAK18,19. To clarify whether BOK is involved in Raptinal-
induced MOMP, we challenged HCT116 BAX/BAK/BOK
triple knock-out (TKO) cells and BAX/BAK/BOK-deﬁ-
cient mouse embryonic ﬁbroblasts with Raptinal. In the
absence of BAX, BAK, and BOK, Raptinal still exerted
cytotoxic effects (Fig. 6a, d), induced caspase-3 and -7
activation (Fig. 6b, e), caused annexin-V/7-AAD positivity
(Fig. 6c) and triggered cytochrome c release from the
mitochondria (Fig. 6f). Collectively, these data argue
against a dependency on BOK for Raptinal-induced
intrinsic apoptosis.
Raptinal-induced loss of mitochondrial function exerts
caspase-independent cytotoxic effects
Apparently, Raptinal is capable to unleash the
mitochondria-controlled death signal within minutes in a
BAX/BAK/BOK-independent manner. Raptinal triggers
release of cytochrome c from the mitochondria (Figs. 4b,
c, 5f, and 6f) and thereby disrupts the electron transport
chain. In line with rapid MOMP induction, 5 min of
exposure to Raptinal was sufﬁcient to decrease the
mitochondrial membrane potential in BAX-, BAX/BAK-
and caspase-9-deﬁcient cells (Fig. 7a–c). Caspase-9-
deﬁcient cells showed almost full-blown protection
when exposed to Raptinal for up to 2 h (Fig. 7d). Over-
night treatment, however, was highly toxic in caspase-9-
and BAX/BAK-deﬁcient cells (Fig. 7d–f). Caspase
inhibition efﬁciently blocked Raptinal-triggered caspase-3
activation even after 24 h (Fig. 8a), abrogated apoptotic
morphology (such as membrane blebbing) of Raptinal-
treated cells (Fig. 8b) and was expectedly sufﬁcient
to protect against TRAIL-induced extrinsic apoptosis
(Fig. 8c). However, blocking caspase activity in HCT116
cells only partially relieved cytotoxicity of short-term (2 h)
Raptinal treatment (Fig. 2f, g) and was even less protective
upon long-term (24 h) exposure (Fig. 8c, d). Thus, MOMP
induction and subsequent loss of mitochondrial function
additionally exert caspase-independent cytotoxic effects.
Collectively, our data support a dual mode of action for
Raptinal to determine a cell’s fate following BAX/BAK/
BOK-independent MOMP (summarized in Fig. 8e): fast
activation of the intrinsic apoptotic pathway (caspase-
dependent cell death) and the loss of mitochondrial
function (caspase-independent cell death).
Discussion
Cancer cells differ widely in their threshold for activa-
tion of the intrinsic apoptotic pathway and consequently
display striking differences in their susceptibility to
chemotherapy-induced apoptosis. A new class of anti-
cancer drugs called ‘BH3 mimetics’ disturbs the sophis-
ticated network of BAX/BAK-regulating BCL-2 family
proteins and increases the readiness for mitochondrial
cytochrome c release. Essentially, BH3 mimetics prime
mitochondria for death and reduce the minimally
required strength of death-promoting stimuli to unleash
mitochondrial apoptosis10. As ‘mitochondria-priming
drugs’, BH3 mimetics show limited efﬁcacy as single
agents in most cancer entities, but act synergistically with
conventional chemotherapies15,20,21. However, the
absence of the pore-forming proteins BAX and/or BAK
renders cancer cells refractory to both, mitochondrial
priming and inducers of intrinsic apoptosis10. From the
latter, Raptinal is a notable exception as (1) the mito-
chondrial priming of target cells does not enhance its
cytotoxic activity (Fig. 2a) and (2) the cytochrome c
release and MOMP occur in a BAX/BAK/BOK-indepen-
dent manner (Figs. 4b, c, 5f, and 6f). Notably, Raptinal
neither directly triggers cytochrome c release in isolated
mitochondria nor via mitochondrial permeability transi-
tion pore (MPTP) formation in the inner mitochondrial
membrane13. Earlier studies already noted that even in the
absence of MPTP, BAX and/or BAK are not always
required for mitochondrial cytochrome c release22,23. Our
data also argue against a decisive role for BOK in
Raptinal-induced MOMP (Fig. 6). Potentially, another yet
unidentiﬁed mechanism for MOMP exists, which may
involve speciﬁc lipids such as ceramide24,25.
Noteworthy, BAX/BAK/BOK-independent MOMP
induction could also unlink mitochondrial priming from a
cell’s readiness to activate the intrinsic apoptotic pathway.
When MOMP is not executed through BAX/BAK-medi-
ated pore-formation in the outer mitochondrial membrane,
disturbing BAX/BAK-regulatory BCL-2 family protein
interaction (e.g., using BH3 mimetics) may have no effect
(see ﬁgure on previous page)
Fig. 4 Raptinal causes cytochrome c release in the absence of the pore-forming proteins BAX/BAK. a HCT116 BAX KO, HCT116 BAX/BAK DKO,
Jurkat J16 and Jurkat BAX/BAK DKO cells were challenged with Raptinal (10 µM) for the indicated periods of time in the presence and absence of the
pan-caspase-inhibitor zVAD-fmk (100 µM). 7-AAD- and annexin-V positivity was analyzed by ﬂow cytometry. b–d HCT116, Jurkat J16, Jurkat BAX/BAK
DKO and Jurkat caspase-9 KO cells were challenged with Raptinal (10 µM) for 15 min (HCT116) or 30 min (Jurkat cells). After washing and lysis,
western blot analyses were performed with whole cell lysates and mitochondria-containing fractions using antibodies speciﬁc for the indicated
proteins. Detection of tubulin (whole cell lysate) and COX IV (mitochondria-containing fraction) served as loading control. e Caspase-9-deﬁcient
Jurkat cells were challenged with Raptinal (10 µM) for the indicated periods of time. 7-AAD- and annexin-V positivity was analyzed by ﬂow cytometry.
For a–e, data shown are representative of at least two experiments performed
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on the apoptotic threshold. Raptinal could therefore be
effective in cancer cells with no/low mitochondrial
priming, which are considered as difﬁcult-to-treat26. In
addition, Raptinal could be unaffected by most mechan-
isms that mediate primary or acquired resistance to BH3
mimetics. For example, the latter can loose their
mitochondria-priming function when binding to BCL-2
proteins is reduced, expression levels of directly BAX-
activating proteins (such as BIM) decrease or nontargeted
BCL-2 pro-survival proteins are upregulated27–30. In stark
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contrast, Raptinal bypasses BAX/BAK (and also BOK)
and is self-sufﬁcient for MOMP induction. Reaching this
point of no return irrevocably condemns a cell to death:
either via intrinsic apoptosis by caspase-9-dependent
activation of downstream effector caspases or loss of
mitochondrial function (Fig. 8e). Admittedly, further
in vivo studies are needed to estimate the risk for clini-
cally unacceptable side-effects of Raptinal. In combina-
tion with novel drug delivery concepts (e.g., conjugation
to target-directing antibodies), the tremendous death-
inducing potential could perspectively be therapeutically
exploitable.
In sum, we show that Raptinal bypasses coordination/
initiation of MOMP by pore-forming BCL-2 family pro-
teins4. Raptinal exerts a dual cytotoxic effect by rapid
activation of the intrinsic apoptotic pathway and simul-
taneous shutdown of mitochondrial function.
Material and methods
Cell lines, antibodies, and reagents
HCT116 cells were obtained from the German Collec-
tion of Microorganisms and Cell Culture (DSMZ,
Braunschweig, Germany). HCT116 BAX/BAK DKO, BAX
KO, and caspase-8 KO cells were kindly provided by
Richard Youle (National Institutes of Health, Bethesda,
USA), Bert Vogelstein (John Hopkins University, Balti-
more, MA, USA) and Hamsa Puthalakath (La Trobe
University, Bundoora, Australia), respectively31–33. BAX/
BAK/BOK-deﬁcient HCT116 cells and MEFs were kindly
provided by Thomas Kaufmann (Institute of Pharmacol-
ogy, University of Bern, Bern, Switzerland). SW48 and
DLD1 cells and BAX/BAK-deﬁcient variants thereof were
purchased from Sigma (Steinheim, Germany). PCI-1 cells
were a gift from Richard Bauer (University of Regensburg,
Germany). Jurkat J16 cells and caspase-9- or BAX/BAK-
deﬁcient variants thereof have been described before34.
All cell lines were maintained in RPMI 1640 medium
(PAN Biotech, Aidenbach, Germany) with 10% (v/v) fetal
calf serum (Sigma). Medium of Jurkat cells was supple-
mented with 100 U penicillin/mL and 0.1 mg streptomy-
cin/mL (PAN Biotech). Antibodies: caspase-3 (#9662),
caspase-9 (#9502), COX IV (#4844), p70S6k (#2708): Cell
Signaling (Beverly, MA, USA); tubulin (#MS-581):
Dunnlab (Asbach, Germany); cytochrome c (ab13575):
abcam (Cambridge, UK). Monoclonal rabbit anti-BOK
(BOK-1-5) was a kind gift from Thomas Kaufmann
(University of Bern, Bern, Switzerland)35. Chemicals:
Raptinal and MTT (3-[4,5-dimethylthiazol-2-yl]−2,5-
diphenyl tetrazolium bromide): Biomol, (Hamburg, Ger-
many); zVAD-fmk (carbobenzoxy-valyl-alanyl-aspartyl-
(Omethyl)-ﬂuoromethylketone): Bachem, (Bubendorf,
Switzerland); zLEHD-fmk: BD Biosciences (Heidelberg,
Germany); ABT-199, ABT-737, S63845 and QVD-OPh:
Hycultec (Beutelsbach, Germany); TRAIL: Apronex
(Jesenice u Prahy, Czech Republic); cOmplete protease
inhibitor cocktail: Roche (Mannheim,
Germany).
MTT-based cell viability assay
Cells were seeded in 96-well plates (Jurkat: 2 × 105 cells/
well; all other cell lines: 2 × 104 cells/well) and challenged
with the indicated concentrations of the indicated sub-
stances in duplicates (technical replicates). Unless indi-
cated otherwise, cell viability was determined 18 h after
stimulation using MTT staining (2 h at 37 °C). Staining
intensity was measured at 595 nm and the mean was
calculated from the technical replicates of each experi-
ment. The mean value for untreated controls was set to
100%. For any other condition, the MTT staining intensity
is given relative to the corresponding untreated group
(% of control). Data points shown are mean values (cal-
culated from 2 technical replicates) of independent
experiments (n ≥ 2–3).
Western blot analysis
Cells were harvested by centrifugation and lysed in 4×
Laemmli sample buffer (8% (w/v) SDS, 0.1M dithiothreitol,
40% (v/v) glycerol, 0.2M Tris, pH 8.0) supplemented with
phosphatase inhibitor cocktails-I and -II (Sigma). Samples
were sonicated and boiled for 5min at 96 °C before proteins
were separated by SDS-PAGE and transferred to PVDF
membranes. To block nonspeciﬁc binding sites, membranes
(see ﬁgure on previous page)
Fig. 5 Raptinal induces intrinsic apoptosis in a variety of BAX/BAK-deﬁcient cell lines. a, b DLD1 and SW48 cells and BAX/BAK-deﬁcient variants
thereof were challenged with the indicated concentrations of Raptinal for 18 h. c Cells were treated with Raptinal (10 µM) for the indicated periods of
time in the presence and absence of the pan-caspase-inhibitor zVAD-fmk (100 µM). 7-AAD- and annexin-V positivity was analyzed by ﬂow cytometry.
d DLD1 and SW48 cells and BAX/BAK-deﬁcient variants thereof were challenged with Raptinal (10 µM) in the presence and absence of the pan-
caspase inhibitor zVAD-fmk (100 µM). Caspase-3/-7 activity was assessed using the ﬂuorogenic substrate (DEVD)2-R110. e, f Cells were challenged with
Raptinal (10 µM) for 60 min. After washing and lysis, western blot analyses were performed with whole cell lysates and mitochondria-containing
fractions using antibodies speciﬁc for the indicated proteins. Detection of tubulin (whole cell lysate) and COX IV (mitochondria-containing fraction)
served as loading control. The asterisk (*) indicates a defect in the CCD sensor of the western blot imaging system. All samples were run on the same
gel, no gels were sliced. For a and b, data points and mean ± SEM from three independent experiments are shown. For c, e, and f, data shown are
representative of at least two experiments performed. d shows individual data points of at least two independent experiments. RFU, relative
ﬂuorescence units
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were incubated in TBS containing 0.1% (v/v) Tween 20 and
5% (w/v) dry milk before primary antibodies of the speci-
ﬁcity of interest were added. Antigen-antibody complexes
were visualized using horseradish peroxidase-conjugated
secondary antibodies (Dako, Hamburg, Germany) and ECL
technology (Pierce, Rockford, IL, USA).
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indicated concentrations of Raptinal for 18 h. Right panel: BOK levels were analyzed in lysates generated from HCT116 BAX/BAK DKO and BAX/BAK/
BOK TKO cells by western blotting. The asterisk (*) indicates a defect in the CCD sensor of the western blot imaging system. All samples were run on
the same gel, no gels were sliced. b HCT116 BAX/BAK DKO and BAX/BAK/BOK TKO cells were challenged with Raptinal (10 µM) for 120 min. Caspase-
3/-7 activity was assessed using the ﬂuorogenic substrate (DEVD)2-R110. c Cells were treated with Raptinal (10 µM) for the indicated periods of time in
the presence and absence of the pan-caspase-inhibitor zVAD-fmk (100 µM). 7-AAD- and annexin-V positivity was analyzed by ﬂow cytometry. d BAX/
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proteins. Detection of tubulin (whole cell lysate) and COX IV (mitochondria-containing fraction) served as loading control. For a and d, data points
and mean ± SEM from three independent experiments are shown. b, e show individual data points of three independent experiments. For c and
f, data shown are representative of at least two experiments performed
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Cytochrome c release by immunoblot
Cytochrome c release by immunoblot was performed
essentially as described previously13. In brief, 3 × 106 cells
were treated with Raptinal for the indicated periods of
time. Cells were harvested, centrifuged (1000 × g, 2 min),
washed with ice-cold PBS, resuspended in 200 μL ice-
cold digitonin permeabilization buffer (75 mM NaCl,
1 mM sodium phosphate monobasic, 8 mM sodium
phosphate dibasic, 250 mM sucrose, 190 μg/mL digito-
nin, protease cocktail inhibitor, pH 7.5) and incubated on
ice for 5 min. Following centrifugation (14,000 × g,
5 min), 150 μL of the supernatant (cytosolic fraction) was
collected. The pellet (mitochondrial fraction) was washed
in 200 μL digitonin permeabilization buffer and lysed in
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Fig 7 Raptinal impairs mitochondrial function. a–c HCT116 BAX KO, HCT116 BAX/BAK DKO, Jurkat BAX/BAK DKO, and Jurkat caspase-9 KO were
treated with Raptinal (10 µM) for the indicated periods of time. Membrane potential of mitochondria was assessed by ﬂow cytometry after staining
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shown. d Jurkat J16, caspase-9 KO, and BAX/BAK DKO were challenged with Raptinal (10 µM) for the indicated periods of time. Cell viability was
assessed by MTT staining. e HCT116 cells and BAX/BAK-deﬁcient variants thereof were challenged with Raptinal (10 µM) for the indicated periods of
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25 μL RIPA lysis buffer (150 mM NaCl, 25 mM Tris, 1%
(v/v) Nonidet P-40, 1% (w/v) sodium deoxycholate, 0.1%
(w/v) SDS, pH 7.5). Forty micrograms of the cytosolic
fraction and 50 μg of the mitochondrial fraction were
resolved by SDS-PAGE. The cytosolic fraction was pro-
bed for tubulin, and the mitochondrial fraction was
probed for cytochrome c oxidase subunit IV (COX IV) to
conﬁrm equal loading.
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Fig. 8 The loss of mitochondrial function complements caspase-dependent cytotoxicity of Raptinal. a HCT116 cells were challenged with
Raptinal (10 µM) for the indicated periods of time in the absence and presence of the pan-caspase inhibitor zVAD-fmk (100 µM). After washing and
lysis, western blot analyses were performed with antibodies speciﬁc for the indicated proteins. Detection of tubulin served as a loading control.
b HCT116 and HCT116 BAX KO cells were challenged with Raptinal (10 µM) for the indicated periods of time in the presence and absence of zVAD-
fmk (100 µM). Morphological changes were documented by bright ﬁeld microscopy. Scale bar: 50 µm. HCT116 cells were challenged with the
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Caspase activity assays
Caspase activity was measured using the caspase-3/-7
activity kit (AAT Bioquest, Sunnyvale, CA, USA)
according to manufacturer’s instructions. Emitted ﬂuor-
escence was quantiﬁed using a Victor3 Multilabel Reader
(Perkin Elmer, Waltham, MA, USA).
Flow cytometry
Cell death was assessed by annexin-V and 7-
aminoactinomycin D (7-AAD) staining. In brief,
HCT116 and Jurkat cells were challenged with 10 µM
Raptinal for 15, 30, and 45min in the presence and
absence of 100 µM zVAD-fmk. Afterwards, cells were
stained with 7-AAD and annexin-V (4 °C for 15min in the
dark) and analyzed immediately using a FACSCanto ﬂow
cytometer (BD Biosciences) following standard proce-
dures36. Mitochondrial membrane potential was mea-
sured using the MitoScreen Kit (#551302, BD Biosciences)
according to manufacturer’s instructions.
Acknowledgements
We thank Richard Youle (National Institutes of Health, Bethesda, USA), Bert
Vogelstein (John Hopkins University, Baltimore, MA, USA), Thomas Kaufmann
(University of Bern, Bern, Switzerland), and Hamsa Puthalakath (La Trobe
University, Bundoora, Australia) for providing HCT116 knock-out cell lines. S.H.
is supported by a fellowship from the Else-Kröner-Fresenius Stiftung. M.E. is
supported by grants from Deutsche Forschungsgemeinschaft (DFG Grant EH
465/2-1), the Universitätsstiftung Helga und Erwin Hartl and the
Universitätsstiftung Angela Schötz-Keilholz.
Author details
1Department of Oral and Maxillofacial Surgery, University Hospital Regensburg,
Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany. 2Institute of Clinical
Microbiology and Hygiene, University Hospital Regensburg, Franz-Josef-
Strauss-Allee 11, 93053 Regensburg, Germany. 3Interfaculty Institute for
Biochemistry, University of Tübingen, 72076 Tübingen, Germany. 4German
Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
Author contributions
M.E., G.K., and S.H. designed the experiments; M.E., S.H., and G.K. performed the
experiments; M.E., S.H., and G.K. analyzed data; K.S.O. provided important
material. M.E. and S.H. wrote the paper.
Conﬂict of interest
The authors declare that they have no conﬂict of interest.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Received: 21 March 2019 Revised: 3 July 2019 Accepted: 3 July 2019
References
1. Bhola, P. D. & Letai, A. Mitochondria-judges and executioners of cell death
sentences. Mol. Cell 61, 695–704 (2016).
2. Gross, A., Jockel, J., Wei, M. C. & Korsmeyer, S. J. Enforced dimerization of bax
results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J.
17, 3878–3885 (1998).
3. Pena-Blanco, A. & Garcia-Saez, A. J. Bax, bak and beyond—mitochondrial
performance in apoptosis. FEBS J. 285, 416–431 (2018).
4. Kalkavan, H. & Green, D. R. Momp, cell suicide as a bcl-2 family business. Cell
Death Differ. 25, 46–55 (2018).
5. Li, P. et al. Cytochrome c and datp-dependent formation of apaf-1/caspase-9
complex initiates an apoptotic protease cascade. Cell 91, 479–489 (1997).
6. Green, D. R. & Llambi, F. Cell death signaling. Cold Spring Harb. Perspect. Biol. 7,
a006080 (2015).
7. Fulda, S. Therapeutic opportunities based on caspase modulation. Semin. Cell
Dev. Biol. 82, 150–157 (2018).
8. Gavathiotis, E., Reyna, D. E., Bellairs, J. A., Leshchiner, E. S. & Walensky, L. D.
Direct and selective small-molecule activation of proapoptotic bax. Nat. Chem.
Biol. 8, 639–645 (2012).
9. Zhao, G. et al. Activation of the proapoptotic bcl-2 protein bax by a small
molecule induces tumor cell apoptosis. Mol. Cell. Biol. 34, 1198–1207 (2014).
10. Merino, D. et al. Bh3-mimetic drugs: blazing the trail for new cancer medicines.
Cancer Cell 34, 879–891 (2018).
11. Kale, J., Osterlund, E. J. & Andrews, D. W. Bcl-2 family proteins: changing
partners in the dance towards death. Cell Death Differ. 25, 65–80 (2018).
12. Singh, R., Letai, A. & Sarosiek, K. Regulation of apoptosis in health and disease:
the balancing act of bcl-2 family proteins. Nat. Rev. Mol. Cell. Biol. 20, 175–193
(2019).
13. Palchaudhuri, R. et al. A small molecule that induces intrinsic pathway
apoptosis with unparalleled speed. Cell Rep. 13, 2027–2036 (2015).
14. Dhar, R., Persaud, S. D., Mireles, J. R. & Basu, A. Proteolytic cleavage of p70
ribosomal s6 kinase by caspase-3 during DNA damage-induced apoptosis.
Biochemistry 48, 1474–1480 (2009).
15. Montero, J. & Letai, A. Why do bcl-2 inhibitors work and where should we use
them in the clinic? Cell Death Differ. 25, 56–64 (2018).
16. Lindsten, T. et al. The combined functions of proapoptotic bcl-2 family
members bak and bax are essential for normal development of multiple
tissues. Mol. Cell 6, 1389–1399 (2000).
17. Wei, M. C. et al. Proapoptotic bax and bak: a requisite gateway to mito-
chondrial dysfunction and death. Science 292, 727–730 (2001).
18. Hsu, S. Y., Kaipia, A., McGee, E., Lomeli, M. & Hsueh, A. J. Bok is a pro-apoptotic
bcl-2 protein with restricted expression in reproductive tissues and hetero-
dimerizes with selective anti-apoptotic bcl-2 family members. Proc. Natl Acad.
Sci. USA. 94, 12401–12406 (1997).
19. Einsele-Scholz, S. et al. Bok is a genuine multi-bh-domain protein that
triggers apoptosis in the absence of bax and bak. J. Cell Sci. 129,
2213–2223 (2016).
20. Oltersdorf, T. et al. An inhibitor of bcl-2 family proteins induces regression of
solid tumours. Nature 435, 677–681 (2005).
21. van Delft, M. F. et al. The bh3 mimetic abt-737 targets selective bcl-2 proteins
and efﬁciently induces apoptosis via bak/bax if mcl-1 is neutralized. Cancer Cell
10, 389–399 (2006).
22. Zamorano, S.et al. A bax/bak and cyclophilin d-independent intrinsic apop-
tosis pathway. PLoS ONE 7, e37782 (2012).
23. Mizuta, T., Shimizu, S., Matsuoka, Y., Nakagawa, T. & Tsujimoto, Y. A bax/bak-
independent mechanism of cytochrome c release. J. Biol. Chem. 282,
16623–16630 (2007).
24. Colombini, M. Ceramide channels and mitochondrial outer membrane per-
meability. J. Bioenerg. Biomembr. 49, 57–64 (2017).
25. Siskind, L. J. & Colombini, M. The lipids c2- and c16-ceramide form large
stable channels. Implications for apoptosis. J. Biol. Chem. 275,
38640–38644 (2000).
26. Ni Chonghaile, T. et al. Pretreatment mitochondrial priming correlates with
clinical response to cytotoxic chemotherapy. Science 334, 1129–1133
(2011).
27. Fresquet, V., Rieger, M., Carolis, C., Garcia-Barchino, M. J. & Martinez-Climent, J.
A. Acquired mutations in bcl2 family proteins conferring resistance to the bh3
mimetic abt-199 in lymphoma. Blood 123, 4111–4119 (2014).
28. Merino, D., et al. Synergistic action of the mcl-1 inhibitor s63845 with current
therapies in preclinical models of triple-negative and her2-ampliﬁed breast
cancer. Sci. Transl. Med. 9, eaam7049 (2017).
29. Kotschy, A. et al. The mcl1 inhibitor s63845 is tolerable and effective in diverse
cancer models. Nature 538, 477–482 (2016).
30. Caenepeel, S. et al. Amg 176, a selective mcl1 inhibitor, is effective in
hematologic cancer models alone and in combination with established
therapies. Cancer Discov. 8, 1582–1597 (2018).
31. Wang, C. & Youle, R. J. Predominant requirement of bax for apoptosis in
hct116 cells is determined by mcl-1’s inhibitory effect on bak. Oncogene 31,
3177–3189 (2012).
Heimer et al. Cell Death and Disease          (2019) 10:556 Page 12 of 13
Ofﬁcial journal of the Cell Death Differentiation Association
32. Zhang, L., Yu, J., Park, B. H., Kinzler, K. W. & Vogelstein, B. Role of bax in the
apoptotic response to anticancer agents. Science 290, 989–992 (2000).
33. Glab, J. A. et al. Dr5 and caspase-8 are dispensable in er stress-induced
apoptosis. Cell Death Differ. 24, 944–950 (2017).
34. Samraj, A. K., Sohn, D., Schulze-Osthoff, K. & Schmitz, I. Loss of caspase-9 reveals
its essential role for caspase-2 activation and mitochondrial membrane
depolarization. Mol. Biol. Cell 18, 84–93 (2007).
35. Echeverry, N. et al. Intracellular localization of the bcl-2 family mem-
ber bok and functional implications. Cell Death Differ. 20, 785–799
(2013).
36. Telford, W., Tamul, K. & Bradford, J. Measurement and characterization of
apoptosis by ﬂow cytometry. Curr. Protoc. Cytom. 77, 9.49.1–9.49.28
(2016).
Heimer et al. Cell Death and Disease          (2019) 10:556 Page 13 of 13
Ofﬁcial journal of the Cell Death Differentiation Association
